This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Euretina Presentation "Adoption Of JETREA® In My Everyday Practice" Confirms Need For A New Paradigm In Treatment Of Symptomatic VMA/ VMT, Including Those Cases Associated With MH

LEUVEN, Belgium, October 1, 2013 /PRNewswire/ --

Largest ever retrospective review of VMA/VMT patients confirms early treatment initiation may stop disease progression and lead to better visual function outcome

  • Retrospective review of patients presenting with vitreomacular adhesion (VMA), vitreomacular traction (VMT), macular hole (MH) with/ without VMA, with or without visual symptoms (n=509)
  • Review period: July 2009 - May 2013, with mean follow up of 2.03 years.
  • VMA is a progressive disease: 16.4% of the eyes diagnosed with VMA progressed to VMT within one year.
  • Exact time and/or impact of progression are patient dependent.
  • Spontaneous resolution of VMA  occurred in 20% of patients with VMT
  • Early treatment may be required to stop further disease progression and improve visual function outcome.

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that Prof. Dr. Peter Stalmans, Department of Ophthalmology, University Hospitals Leuven, Belgium, delivered a presentation entitled "Adoption of JETREA ® in My Everyday Practice", at the recent EURETINA annual meeting of European Society of Retina Specialists in Hamburg.

In his presentation, Prof. Stalmans provided details of the largest retrospective, observational study to date, that looked at his "real world" experience with patients with vitreomacular adhesion (VMA), vitreomacular traction (VMT) and macular hole (MH).  

Prof. Stalmans is working at a large, tertiary care ophthalmology center in Leuven ( Belgium). The Leuven center sees 50,000 ambulatory patients every year and conducts around 2500 intravitreal injections and 7000 surgical procedures per annum.  The retrospective study is leveraging data collected from electronic medical records gathered at the center between July 2009 and May 2013.  

During EURETINA, Prof Stalmans also provided insights into his own successful clinical experience with JETREA ® when treating patients with early VMT and MH.

Commenting on his presentation Prof. Dr. Peter Stalmans, Department of Ophthalmology, University Hospitals  Leuven says, " This is the largest retrospective study conducted using high resolution OCT technology. The data collected clearly shows that VMA/VMT is a progressive condition and that spontaneous resolution of VMT is a low occurrence. Based on our findings I believe that early treatment of these patients may be important if we are to help them by resolving debilitating symptoms such as metamorphopsia, and further sight threatening complications such as macular hole. My own experience of treating patients experiencing metamorphopsia early with  JETREA ® has been extremely good with the vast majority of patients experiencing resolution of their traction. I look forward to treating many more patients with this novel drug which I believe will play a key role in the treatment of a wide range of patients with VMT. "

" This new VMA/VMT patient review is the largest ever available, " says Dr. Patrik De Haes, CEO of ThromboGenics. " For the first time, we are able to look at  ' real life '  data provided from a tertiary center, " he continues. " We are pleased to see how the results highlight the opportunity for JETREA ® as an early treatment option for those patients who would normally only be observed. These new data and  ' real life '  insights will help us to further educate the community about the risk of disease progression and the patient benefit of early treatment, " he concludes.

A video interview with Prof. Stalmans at Euretina is available at this link: http://eyetube.net/series/daily-coverage-hamburg-2013/mesaj/

About ThromboGenics

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs